Keytruda (pembrolizumab; Merck) plus chemotherapy administered as neoadjuvant treatment and then as monotherapy postsurgery produced a statistically significant improvement in overall survival in patients with high-risk early-stage triple-negative breast cancer.
Wyatt discusses how these devices are changing patient monitoring in clinical trials.
Biotechs can successfully overcome bottlenecks in time-to-market for new drugs by embracing contracting innovations with the same passion applied to research breakthroughs.
New collaboration offers end-to-end solution, supplying and training sites on ophthalmic medical imaging equipment.
Results of the trial found that monotherapy led to clinical benefit in 16.7% of patients, including complete and partial responses in renal cell carcinoma (RCC) patients.
Expanded collaboration seeks to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases.
Study results showed a 36% and 25% reduction in loss of asthma control (LOAC) with high and low doses of rilzabrutinib.
New agreement leverages Beaconcure’s technology to streamline review processes.
Newly published consensus statement outlines RCT questions ranked according to importance and feasibility.
BTX-A51 aims to address GATA3 mutations, which affect around 15% of breast cancer patients.
A more user-centered design can allow increased flexibility in the development of eCOA platforms, driving better engagement and participation.
Results from both trials demonstrated a significant reduction in annual asthma exacerbations over 52 weeks.
ICON plc CEO Steve Cutler discussed how strategic partnerships are driving advancements in clinical trials.
Despite limitations to its widespread use within healthcare, there is great potential for ChatGPT’s application in drug development.
Results of the trial indicated that efsitora is non-inferior in A1C reduction compared to daily basal insulins.
Retrospective cohort study sought to identify similarities between response- and progression-based end points in clinical trials and weighted observational cohorts of patients.
Companies must be able to defend the fidelity and confidentiality of all records and data generated throughout a product’s entire lifecycle, starting with the earliest points in research.
Sotyktu (deucravacitinib; Bristol Myers Squibb) is an oral, selective, allosteric tyrosine kinase 2 inhibitor that produced clinically meaningful improvements in Psoriasis Area and Severity Index scores among adult patients with moderate-to-severe plaque psoriasis.
Panna Sharma, CEO of Lantern Pharma, discusses LP-284, using their RADR during testing, ensuring global use, and what the future holds.
In the fifth and final part of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints look ahead to the future of risk-based quality management and what adoption will look like.
Once-weekly subcutaneous injection of CT-388 produced significant weight loss in healthy adults with obesity compared with placebo across 24 weeks in an early phase trial.
Promising scientific advances are pacing oncology drug development.
In part 4 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints touch on what risks companies leave themselves susceptible to without the adoption of risk-based approaches.
Sharing an entertaining dive into the origins, milestones, and future of behavioral economics—where lessons can be applied to clinical practice.
Leqembi (lecanemab-irmb) was previously granted fast track designation by the FDA for a subcutaneous version of the drug to treat Alzheimer disease in patients with mild cognitive impairment or the mild dementia stage of the disease.
Expanded relationship will utilize Medidata’s artificial intelligence solutions.
The potential of PBPK modeling in answering key questions around these drugs.
In the Complete Response Letter to Dynavax, the FDA stated that the supplemental Biologic License Application based on findings from the Phase I HBV-24 trial lacked sufficient data to support a full evaluation of the efficacy or safety of a four-dose Heplisav-B regimen in adults on hemodialysis.
A forum of prominent industry stakeholders highlights the challenges for patients in navigating the multiple legal, regulatory, and ethical barriers to cross-border participation.
In part 3 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management.
